The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease

被引:50
作者
Brettschneider, Johannes
Petzold, Axel
Schoettle, Daniel
Claus, Annett
Riepe, Matthias
Tumani, Hayrettin
机构
[1] Univ Ulm, Dept Neurol, DE-89081 Ulm, Germany
[2] Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England
关键词
Alzheimer's disease; cerebrospinal fluid; markers; diagnostic; NfH(SMI35);
D O I
10.1159/000091436
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Aims: Attempting to improve the cerebrospinal fluid (CSF) diagnosis of Alzheimer's disease ( AD), the neurofilament heavy chain isoform, NfH(SMI35) was compared to other CSF markers [ total tau, phospho-tau, amyloid beta 1 - 42 (A beta 42), the ratio of amyloid beta fragments A beta 42/A beta 40 (A beta ratio)]. Methods: CSF levels were determined in patients with AD (n = 109), mild cognitive impairment (MCI, n = 25), frontotemporal dementia ( n = 15), vascular dementia ( VD, n = 41), and controls ( n = 58). Results: CSF NfH(SMI35) was elevated in AD and VD as compared to controls ( p < 0.05). Total tau was higher in AD as compared to controls ( p < 0.05). CSF phospho-tau was elevated in AD as compared to controls and VD ( p < 0.05 each). CSF A beta 42 and A beta ratios in AD were lower than in MCI and controls ( p < 0.05 each). Conclusion: The diagnostic potential of NfH(SMI35) is not superior to that of other CSF markers. Copyright (C) 2006 S. Karger AG, Basel.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 33 条
[1]   Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].
Andreasen, N ;
Vanmechelen, E ;
Van de Voorde, A ;
Davidsson, P ;
Hesse, C ;
Tarvonen, S ;
Räihä, I ;
Sourander, L ;
Winblad, B ;
Blennow, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305
[2]   [18F]FDG-PET in patients with Alzheimer's disease:: Marker of disease spread [J].
Bittner, D ;
Grön, G ;
Schirrmeister, H ;
Reske, SN ;
Riepe, MW .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2005, 19 (01) :24-30
[3]   CSF total tau, aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease [J].
Blennow, K ;
Vanmechelen, E ;
Hampel, H .
MOLECULAR NEUROBIOLOGY, 2001, 24 (1-3) :87-97
[4]  
BRETTSCHNEIDER J, IN PRESS MULT SCLER
[5]   Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 [J].
Buerger, K ;
Zinkowski, R ;
Teipel, SJ ;
Tapiola, T ;
Arai, H ;
Blennow, K ;
Andreasen, N ;
Hofmann-Kiefer, K ;
DeBernardis, J ;
Kerkman, D ;
McCulloch, C ;
Kohnken, R ;
Padberg, F ;
Pirttilä, T ;
Schapiro, MB ;
Rapoport, SI ;
Möller, HJ ;
Davies, P ;
Hampel, H .
ARCHIVES OF NEUROLOGY, 2002, 59 (08) :1267-1272
[6]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[7]   Subjective memory complaints:: Objective neural markers in patients with Alzheimer's disease and major depressive disorder [J].
Grön, G ;
Bittner, D ;
Schmitz, B ;
Wunderlich, AP ;
Riepe, MW .
ANNALS OF NEUROLOGY, 2002, 51 (04) :491-498
[8]   Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease [J].
Grossman, M ;
Farmer, J ;
Leight, S ;
Work, M ;
Moore, P ;
Van Deerlin, V ;
Pratico, D ;
Clark, CM ;
Coslett, HB ;
Chatterjee, A ;
Gee, J ;
Trojanowski, JQ ;
Lee, VMY .
ANNALS OF NEUROLOGY, 2005, 57 (05) :721-729
[9]   Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].
Hulstaert, F ;
Blennow, K ;
Ivanoiu, A ;
Schoonderwaldt, HC ;
Riemenschneider, M ;
De Deyn, PP ;
Bancher, C ;
Cras, P ;
Wiltfang, J ;
Mehta, PD ;
Iqbal, K ;
Pottel, H ;
Vanmechelen, E ;
Vanderstichele, H .
NEUROLOGY, 1999, 52 (08) :1555-1562
[10]   Diagnostic accuracy of Alzheimer's disease: A clinicopathological study [J].
Jellinger, KA .
ACTA NEUROPATHOLOGICA, 1996, 91 (02) :219-220